Metabolic profiling of alcohol consumption in 9778 young adults

Peter Würtz, Sarah Cook, Qin Wang, Mika Tiainen, Tuulia Tynkkynen, Antti J. Kangas, Pasi Soininen, Jaana Laitinen, Jorma Viikari, Mika Kähönen, Terho Lehtimäki, Markus Perola, Stefan Blankenberg, Tanja Zeller, Satu Männistö, Veikko Salomaa, Marjo-Riitta Järvelin, Olli T. Raitakari, Mika Ala-Korpela, and David A. Leon

Abstract

Background: High alcohol consumption is a major cause of morbidity, yet alcohol is associated with both favourable and adverse effects on cardiometabolic risk markers. We aimed to characterize the associations of usual alcohol consumption with a comprehensive systemic metabolite profile in young adults.

Methods: Cross-sectional associations of alcohol intake with 86 metabolic measures were assessed for 9778 individuals from three population-based cohorts from Finland.
Metabolic changes associated with change in alcohol intake during 6-year follow-up were further examined for 1466 individuals. Alcohol intake was assessed by questionnaires. Circulating lipids, fatty acids and metabolites were quantified by high-throughput nuclear magnetic resonance metabolomics and biochemical assays.

**Results:** Increased alcohol intake was associated with cardiometabolic risk markers across multiple metabolic pathways, including higher lipid concentrations in HDL subclasses and smaller LDL particle size, increased proportions of monounsaturated fatty acids and decreased proportion of omega-6 fatty acids, lower concentrations of glutamine and citrate ($P < 0.001$ for 56 metabolic measures). Many metabolic biomarkers displayed U-shaped associations with alcohol consumption. Results were coherent for men and women, consistent across the three cohorts and similar if adjusting for body mass index, smoking and physical activity. The metabolic changes accompanying change in alcohol intake during follow-up resembled the cross-sectional association pattern ($R^2 = 0.83$, slope $= 0.72 \pm 0.04$).

**Conclusions:** Alcohol consumption is associated with a complex metabolic signature, including aberrations in multiple biomarkers for elevated cardiometabolic risk. The metabolic signature tracks with long-term changes in alcohol consumption. These results elucidate the double-edged effects of alcohol on cardiovascular risk.

**Key words:** Alcohol, risk factors, metabolomics, fatty acids, metabolic profiling

---

**Introduction**

Alcohol consumption is one of the leading risk factors for death and disability, accounting for almost 3 million annual deaths globally and 3.9% of life-years lost to disease. The harmful effects of alcohol use are well characterized and uncontroversial for some conditions, such as liver cirrhosis, injuries and several cancers. However, considerable debate remains as to the nature of the association between the amount of alcohol consumed and cardiovascular disease. Observational studies have generally found a U-shaped relationship between alcohol intake and cardiovascular disease risk, with lower risk in moderate drinkers compared with...
both abstainers and heavier drinkers. Whether this effect is
causal or due to confounding remains an unresolved issue. A
recent Mendelian randomization study on ADH1B1 sug-
gested adverse effects of any amount of alcohol on coronary
heart disease. Intervventional studies on the effects of alcohol
on circulating risk markers have indicated favourable effects
on adiponectin, fibrinogen and high-density lipoprotein
(HDL) cholesterol, and the causal effect of alcohol on the
latter has been supported by Mendelian randomization stud-
ies on ALDH2. However, accumulating evidence suggests
that these markers are not causally related to cardiomet-
aric risk, and the apparent cardioprotective role of
modest alcohol consumption may therefore not be ascribed
to mediation through these measures. Novel systemic bio-
markers reflecting both alcohol intake and cardiovascular
risk could serve as molecular intermediates to bridge the
intricate exposure-disease relation.

The physiological effects of alcohol involve multiple
metabolic pathways that extend beyond routine risk
markers. Metabolomics provides a fine-grained snap-
shot of systemic metabolism and can therefore clarify the
metabolic signatures of alcohol intake. Such metabolite
profiling approaches are increasingly used also in relation
to alcohol research, but most biomarkers associated with alco-
hol intake have not been related to disease outcomes. Serum nuclear magnetic resonance (NMR) metabolomics
enables quantitative metabolite profiling of large cohorts
and biobank collections at low costs. This high-throughput
methodology provides detailed lipoprotein subclass profil-
ing, as well as quantification of fatty acids and small mol-
ecules such amino acids, of which many have recently been
linked with the risk for cardiovascular disease and type 2
diabetes. Associations of these biomarkers with alcohol
intake could therefore elucidate the beneficial and harmful
metabolic processes related to alcohol consumption.

To characterize metabolic signatures of habitual alcohol
consumption, we conducted serum NMR metabolomics of
9778 young adults from three population-based cohorts in
Finland. We further assessed how change in alcohol con-
sumption was accompanied by changes in the systemic
metabolic profile. This clarifies how the detailed metabolic
signature of alcohol intake tracks with changes in alcohol
intake and minimizes influences of confounding. Finally,
we examined the continuous shapes of the metabolic as-
sociations with alcohol intake to uncover potentially non-
linear relationships with cardiovascular risk markers.

Methods

Study populations

All study participants provided written informed consent,
and study protocols were approved by the local ethics
committees. The study population comprised three
population-based cohorts: the Northern Finland Birth
Cohort of 1966 (NFBC-1966; n = 6007 participants in the
31-year field study, among whom n = 5711 had metabolic
profiling data available and n = 5025 also data on alcohol
intake); the FINRISK 1997 study (n = 8444 partici-
ants aged 24–74, among whom n = 7603 had metabolic
profiling data available and n = 6088 also data on alcohol
intake, n = 2900 of these eligible individuals were aged
24–45); and the Cardiovascular Risk in Young Finns Study
(YFS, n = 2283 aged 24–39 at the first time-point of
metabolic profiling, among whom n = 2247 had metabolic
profiling data and n = 2214 also data on alcohol in-
take). To minimize reverse causality and to capture as
far as possible physiological rather than pathological asso-
ciations, analyses were restricted to individuals under 46
years of age (n = 10 318 out of 13 227 with metabolic pro-
file and alcohol data available). In addition, pregnant
women (n = 270), participants using lipid-lowering medi-
cation (n = 17) and individuals reporting alcohol consump-
tion >500 g/week (n = 74) were excluded, yielding 9778
participants aged 24–45 for the present meta-analysis of
cross-sectional associations. A subset of 1466 participants
from YFS who were followed up again after 6 years (2001
to 2007) were assessed in longitudinal analyses. These
longitudinal analyses were further validated for 1401 YFS
participants with data on alcohol and metabolite levels at
10-year follow-up (2001 to 2011). Body mass index (BMI)
and blood pressure were measured as part of the clinical
examination. Current smoking status and physical activity
index (assessed as metabolic-equivalent of task in NFBC-
1966 and YFS, and as high or low leisure time activity in
FINRISK) were assessed by questionnaires. Further de-
tails of the study populations are described in
Supplementary Methods, available as Supplementary data
at IJE online.

Alcohol consumption

Alcohol intake was assessed from questionnaires. In the
NFBC-1966, the average volume of ethanol consumed per
week was estimated from beverage-specific questions on
usual weekly frequency of drinking and usual volume con-
sumed per occasion for beer, cider and long drinks (pre-
mixed ready-to drink cocktails with ethanol volume
approximately 5.5%), light wine, mild, strong or home-
made wine (in 16-cl glasses), and spirits (in 4-cl restaurant
portions). In the FINRISK study, the volume of ethanol
consumed in the past week was calculated from beverage-
specific questions on consumption of beer, cider and long
drinks (measured in 0.33-l bottles), wine (in 12-cl glasses)
and spirits (in 4-cl restaurant portions). In the YFS, the
volume of ethanol consumed in the past week was estimated from beverage-specific questions on the volume of medium beer (4.7%), strong beer (> 4.7%), wine, cider/long drinks, and spirits consumed. Questions on beer, cider and long drinks referred to 0.33-l bottles, wine to glasses and spirits to 4-cl portions. The alcohol intake was summarized as volume of ethanol in grams per week for all three cohorts, with the data harmonized to the volume of ethanol estimation across the different study questionnaires. Participants with alcohol consumption above 500 g/week (approximately 99th percentile) were excluded to avoid the increased likelihood of these values being spurious due to implausible values.

Metabolic profiling
A high-throughput serum NMR metabolomics platform was used to quantify 76 circulating lipid and metabolite measures in the three cohorts. This metabolomics platform provides simultaneous quantification of routine lipids, lipid concentrations of 14 lipoprotein subclasses and major subfractions, and further abundant fatty acids, amino acids, ketone bodies and gluconeogenesis-related metabolites in absolute concentration units (Supplementary Table S1, available as Supplementary data at IJE online). The platform has been applied extensively in epidemiological studies; details of the experimentation and the analytical repeatability of the biomarker quantification have been described elsewhere. We also analysed 10 additional protein and hormonal biomarkers measured in at least two cohorts. These were high-sensitivity C-reactive protein (CRP), phospholipase activity, gamma glutamyl transferase (GGT), alanine aminotransferase (ALT), testosterone, sex-hormone binding globulin (SHBG), adiponectin, leptin, vitamin D and insulin; they were measured using conventional clinical chemistry and mass spectrometry as described in Supplementary Methods, available as Supplementary data at IJE online. Inclusion of these additional measures was selected a priori because suspected association with alcohol consumption and cardiovascular risk.

Statistical analysis
Metabolic measures with skewness > 2 were first log-transformed. All metabolic measures were subsequently scaled to standard deviation (SD) units separately for each cohort to enable comparison of association magnitudes. Due to the correlated nature of the metabolic measures, more than 95% of the variation in the metabolomic data in all three cohorts was explained by 32 principal components. Multiple testing correction therefore accounted for 32 independent tests using the Bonferroni method, resulting in P < 0.0016 considered statistically significant.

Linear regression models were fitted for each metabolic measure with ethanol intake as the explanatory variable and the metabolite concentration as the outcome. All models were adjusted for age and sex. Results were analysed separately for each cohort and combined using fixed effect inverse-variance weighted meta-analysis after confirming the consistency across the three cohorts. Sensitivity analyses were conducted with additional adjustment for BMI, smoking and physical activity. Association magnitudes are presented combined for men and women in the main text since association magnitudes were generally similar for both sexes; sex-stratified analyses are presented in the Supplementary Appendix, available as Supplementary data at IJE online.

Data on alcohol consumption and metabolite levels were available for 1466 individuals from YFS at 6-year follow-up; this was used to examine whether changes in metabolite concentrations track with changes in alcohol consumption during follow-up. For these longitudinal analyses, linear regression models were fitted with 6-year change in metabolite concentration as the outcome and 6-year change in ethanol intake as the explanatory variable with adjustment for age and sex. Baseline and follow-up metabolite concentrations were standardized to SD units at baseline, so that cross-sectional and longitudinal associations are directly comparable. The resemblance between the overall cross-sectional and longitudinal association patterns was quantified using the R² goodness-of-fit and the slope of the linear fit. To further validate the consistency between the cross-sectional and longitudinal associations, the association patterns were also compared using R² for 1401 individuals with alcohol and metabolite data at 10-year follow-up.

The continuous shape of the metabolic associations with alcohol consumption were examined descriptively using local quadratic regression fitting, with each smoothing function segment evaluated at 25 points through the range of ethanol intake. To adjust for age and sex, the absolute concentration of each metabolic measure was first regressed for age and sex in each cohort and the resulting residuals were pooled before fitting and rescaled to absolute units. Equivalent analyses were done stratified by sex. Statistical analyses were conducted using R 3.1.

Results
The study population comprised 9778 young adults from three Finnish population-based cohorts with
comprehensive lipid and metabolite profiling data. Clinical characteristics of the three cohorts are shown in Table 1. The mean age was 33 years (range 24–45) and 53% of the participants were women. The median consumption of alcohol was around three drinks per week (36 grams of ethanol) in all three cohorts. Despite differences in the questionnaires on alcohol usage relating to usual intake or consumption during the week preceding the clinical examination, the distribution of alcohol intake was similar across the three cohorts (Supplementary Figure S1, available as Supplementary data at IJE online). Mean concentrations of the metabolic measures are listed in Supplementary Table S1, available as Supplementary data at IJE online.

Alcohol associations with lipoprotein lipids

Cross-sectional associations of alcohol consumption with 38 lipoprotein and lipid measures are shown in the left panel of Figure 1; the corresponding associations of change in alcohol consumption with change in lipid concentrations are shown in the right panel. The overall cross-sectional association pattern was recapitulated in the longitudinal association pattern: the lipids most strongly associated with alcohol consumption also displayed the highest responsiveness to changes in alcohol intake during follow-up. Increased alcohol consumption was modestly associated with elevated lipid levels within the largest very-low-density lipoprotein (VLDL) subclasses, whereas associations with lipids in the low-density lipoprotein (LDL) subclasses appeared very weak. However, increased alcohol intake was robustly associated with larger VLDL particle size, whereas LDL particle size displayed a strong inverse association. Prominent associations were observed between higher alcohol consumption and higher lipid concentrations for all high-density lipoprotein (HDL) subclasses, particularly for the medium-sized and small HDL particles. Concomitantly, the cholesterol and phospholipid concentrations in the HDL subclasses were robustly elevated in relation to higher alcohol intake, whereas triglyceride in HDL were only modestly elevated. When examining the continuous association shapes, HDL-related measures were broadly linear or modestly declining in slope across the range of alcohol consumption, whereas more complex continuous association shapes were observed for the apolipoprotein B-carrying lipids (Supplementary Figure S2, available as Supplementary data at IJE online). Here, inverse associations were observed in the first segment up to 50 g/week, with convex association curves for men and declining slopes for women. The non-linear association shapes for these lipid measures partly mask the associations in the linear models. The pattern of lipid associations with alcohol intake was highly coherent across all three cohorts analysed (Supplementary Figure S3, available as Supplementary data at IJE online). Association magnitudes in absolute concentration units are listed in Supplementary Table S1, available as Supplementary data at IJE online. For example, 100 g higher ethanol intake per week (corresponding to about eight drink units; 1.29 SD) was associated with 0.073 mmol/l higher HDL cholesterol.

Alcohol associations with fatty acids

The cross-sectional and longitudinal associations of alcohol consumption with circulating fatty acid levels are
shown in Figure 2. The association pattern observed in the cross-sectional analyses resembled that seen within person over the 6-year follow-up period, except for omega-3 fatty acid related measures. Higher alcohol intake was robustly associated with an increase in the absolute concentrations of total fatty acids, saturated fatty acids and monounsaturated fatty acids (MUFA). In contrast, absolute concentrations of omega-6 fatty acids were not associated with alcohol consumption. However, the proportions of fatty acid levels to total fatty acids are often considered better
indicators of metabolic risk. These measures displayed a pattern of strongly elevated MUFA ratio with higher alcohol consumption, whereas omega-6 fatty acid ratio was strongly inversely associated with alcohol intake. These fatty acid associations were linear across the range of alcohol intake. The association magnitudes of MUFA ratio (0.26 SD higher per 100 g weekly ethanol intake, equivalent to 0.90%) and omega-6 proportion (0.23 SD lower per 100 g weekly ethanol intake, equivalent to 0.87%) were stronger than those of HDL cholesterol. The association of alcohol intake with the proportion of omega-3 fatty acid was only weakly positive cross-sectionally and inconsistent with this longitudinally.

Alcohol associations with metabolites and hormones
The cross-sectional and longitudinal associations of alcohol consumption with circulating amino acids, gluconeogenesis metabolites and various inflammatory and hormonal measures are shown in Figure 3. The strongest associations for low-molecular-weight metabolites were observed for glutamine and citrate, both inversely associated with increased alcohol intake. Whereas most of the small molecule metabolites were not strongly associated with alcohol consumption based on the linear models, subtle non-linear association shapes were evident for several measures, e.g. phenylalanine and glycerol. Higher alcohol intake was modestly associated with increased levels of several amino acids, glycolysis and gluconeogenesis-related metabolites as well as glycoprotein acetyl and C-reactive protein, markers of chronic inflammation. Higher testosterone was associated with alcohol consumption for both men and women, but an inverse association with SHBG was only observed for men. Higher alcohol intake was also associated with the adipokine adiponectin and elevated circulating levels of the liver enzymes GGT and ALT. Although the power to denote statistical significance was limited, the changes in metabolite and hormonal concentrations associated with 6-year change in alcohol consumption broadly matched with the cross-sectional associations.

Consistency of cross-sectional and longitudinal association patterns
The resemblance between the overall metabolic association patterns of alcohol consumption observed cross-sectionally and longitudinally is illustrated in Figure 4. The association magnitudes followed a straight line, with goodness of fit $R^2 = 0.83$ (95% confidence intervals 0.77–0.90). The slope of the linear fit was 0.72 ± 0.04, indicating that each unit change in alcohol intake was on average accompanied by a slightly weaker change in the metabolic profile compared with that estimated from the cross-sectional analyses. The consistency between the cross-sectional and longitudinal associations was even stronger if only comparing measures associated with alcohol intake at $P < 0.0016$ ($R^2 = 0.87$). The match of the association patterns was also similar when cross-sectional and longitudinal associations were compared only for the same 1466 individuals.
Data on metabolic profiling and alcohol intake were also available at 10-year follow-up from the same study population; strongly coherent results were obtained when the longitudinal and cross-sectional association patterns were compared at this extended follow-up duration ($R^2 = 0.77$).

**Sensitivity analyses**

The cross-sectional associations of alcohol intake with metabolic measures were generally concordant across the three cohorts (Supplementary Figure S3, available as Supplementary data at IJE online). Men and women displayed a similar overall pattern of metabolic associations.
with alcohol intake (Supplementary Figure S4, available as Supplementary data at IJE online). Association magnitudes in units of 100 g/week were generally stronger for women; however, Pearson’s correlations between alcohol intake and the metabolic measures are broadly similar for men and women because of the higher variation in alcohol intake for men (1 SD in ethanol intake = 91 g/week for men and 52 g/week for women). Although some sex differences were apparent from the linear modelling, e.g. inverse associations for LDL subclasses for women only, these were mostly related to subtle differences in the continuous association shapes. Surprisingly, adjustment for BMI, smoking status and physical activity index had little effect on strength of association (3% attenuation on average; Supplementary Figure S5, available as Supplementary data at IJE online). The results were also similar if additional adjustment for baseline alcohol was made in the longitudinal modelling. All results were essentially unaltered if excluding the 1388 individuals who abstained from alcohol consumption according to the questionnaires.

Continuous shape of metabolic associations with alcohol

The shapes of the metabolic associations as a function of alcohol consumption are shown for all 86 metabolic measures in Supplementary Figure S2. The continuous association shapes for 12 selected measures are illustrated in Figure 5. For most of the metabolic measures strongly correlated with alcohol intake, the shapes of association were approximately linear. This is exemplified for MUFA and omega-6 ratios, relative to total fatty acids, as well as glutamine. Other metabolic measures displayed non-linear association shapes, with strong initial increase (e.g. medium HDL lipids) or decrease (e.g. citrate) that became less steep at high ranges of alcohol consumption. Omega-3 ratio displayed a steep increase followed by a plateau association. A substantial number of metabolic measures displayed more complex non-linear associations, as exemplified for medium VLDL and medium LDL lipid concentrations in Figure 5. Total triglycerides and LDL cholesterol, respectively, displayed similar shapes as these subclass measures. U-shaped curves for modest alcohol intake (up to 200 g/week)
Figure 5. Lipid and metabolite concentrations as a function of alcohol consumption for 12 selected metabolic measures (n = 9978). The shaded curves denote the 95% confidence intervals of the local polynomial regression fits. Associations were adjusted for age, sex and cohort. The continuous shapes of associations for all 86 metabolic measures are shown for men and women in Supplementary Figure S2, available as Supplementary data at IJE online.
ethanol/week, approximately two drinks per day; 93% of the study population in this range) were particularly prominent for men in the case of atherogenic lipid measures (Supplementary Figure S2). However, similar convex shapes were observed for both men and women in this range of alcohol intake for other cardiometabolic risk biomarkers, such as phenylalanine.

Discussion

Metabolic profiling of almost 10 000 young adults revealed an intricate pattern of lipid and metabolite associations with usual alcohol consumption. The molecular signature linked with alcohol intake cover multiple metabolic pathways, including lipoprotein subclasses, fatty acid composition, glutamine and citrate regulation and hormonal balance. These metabolic perturbations comprise a mixture of both favourable and adverse effects in relation to cardiovascular disease and all-cause mortality risk. The pattern of metabolic changes accompanying intake of alcohol intake at 6-year follow-up was highly consistent with the metabolic association pattern observed at a single time point, suggesting that the metabolomic signature of alcohol consumption tracks with long-term changes in alcohol use. Although potential causal disease relations remain unclear for many of the metabolic biomarkers, our findings provide improved understanding of the diverse molecular processes related to alcohol intake, and may help to clarify the complex mediation between alcohol and cardiovascular risk.

The molecular underpinnings of the apparent cardioprotective effects of modest alcohol consumption reported in observational studies remains contentious. Numerous observational and interventional studies have found increased HDL cholesterol and apolipoprotein A-I levels with higher alcohol intake. These lipoprotein measures serve here as positive controls, along with the liver enzymes markers, and set the association magnitudes into perspective: several of the novel metabolic biomarkers were as strongly associated with alcohol intake as HDL cholesterol and GGT. Nonetheless, accumulating evidence argues against a causal role of HDL cholesterol in cardiovascular disease, so other underpinning mediators may be required to explain potential cardioprotective effects of moderate alcohol consumption. Medium-sized and small HDL subclasses displayed the most pronounced associations, whereas the association slopes for larger HDL subclasses levelled off after initial rapid increase. However, the lipid levels of medium and small HDL are weaker biomarkers of lower cardiovascular risk than those of large HDL. If changes in HDL metabolism due to alcohol intake are reflecting some underlying cardioprotective mechanism, then the effects appear less favourable than assumed by assessing only HDL cholesterol, since this measure combines subclasses with heterogeneous associations.

In contrast to HDL cholesterol, the causal atherogenic role of LDL particles is well established and increasingly clear also for the triglyceride-rich lipoprotein particles. These apolipoprotein B-carrying particles displayed weak or no association with alcohol intake in the standard linear models; however, inverse associations were observed for women in sex-stratified analyses and men displayed U-shaped associations, with most favourable lipid levels observed around 50 grams of ethanol intake per week. Similar sex differences have been observed previously for LDL cholesterol. Although only a small fraction of the study population were heavy drinkers, we recapitulated the anticipated low levels of LDL subclass lipids at the highest alcohol range. However, LDL particle size strongly decreased along with increasing alcohol intake, and some studies have related this measure to higher cardiovascular risk. These results illustrate how lipoprotein subclass profiling may uncover potentially unfavourable risk effects missed by routine biomarkers. Further, the non-linear shapes underline the need to assess continuous associations with alcohol intake for both established and emerging biomarkers of cardiometabolic risk. The more favourable circulating levels of atherogenic lipids observed for individuals with modest alcohol consumption may partly contribute to explain the apparent cardioprotective effect for moderate drinkers; however, the association magnitudes were too weak to fully attribute the consistent reports of the U-shaped association with cardiovascular risk to these lipid measures.

The relation between alcohol intake and the fatty acid balance revealed a mixed set of associations, with mostly adverse aberrations in terms of biomarkers for cardiovascular risk. Subtle sex differences and non-linear association shapes contributed to the complex picture, e.g. for omega-3 fatty acid ratio. MUFA ratio displayed the strongest association with alcohol intake among all the 86 metabolic measures analysed. Contrary to the dietary intake of this measure, higher circulating MUFA ratio is a biomarker of higher cardiovascular and diabetes risk. Likewise, the robust association of alcohol intake with lower proportion of omega-6 fatty acids is also related to higher cardiometabolic risk. Our findings are consistent with much smaller studies on men at high risk for cardiovascular disease or suffering from alcohol dependence. The prominent fatty acid associations were essentially linear across the entire range of alcohol consumption and were corroborated by the longitudinal analyses. Although the causality of these fatty acids remains unclear, the primarily adverse changes in these emerging risk markers indicate
also unfavourable metabolic aberrations with modest alcohol consumption.

Recent metabolic profiling studies have linked several circulating amino acids and other small molecules with the risk for cardiovascular disease, type 2 diabetes and all-cause mortality. Dietary determinants of these circulating biomarkers remain poorly understood. In the present analyses, only few low-molecular-weight metabolites were strongly associated with alcohol intake. The most prominent associations were for citrate and glutamine, both strongly inversely associated with alcohol intake but otherwise weakly correlated with established risk factors. Our results are supported by a smaller metabolomics study of alcohol intake in Japanese men. Higher citrate levels have been linked with modestly lower risk for cardiovascular disease, but simultaneously with higher risk of all-cause mortality. The biological underpinnings of citrate’s links with disease remain elusive. Higher circulating glutamine is associated with lower risk for cardiovascular disease and type 2 diabetes. Glutamine and citrate are connected via the citric acid cycle and both metabolites play critical roles at the centre of cancer cell metabolism. Multiple other metabolites and hormones also displayed associations with alcohol intake; however, further investigations are required to clarify whether these molecular perturbations could arise as a combined effect of alcohol intake on multiple metabolic pathways.

Our study has both strengths and limitations. The large sample size provides robust evidence for many novel metabolic markers of alcohol consumption, in particular since results were coherent across the three cohorts despite differences between the measures of alcohol intake. Although our study was conducted solely in the homogeneous Finnish population, many of the strongest metabolic biomarkers have been related to alcohol intake in smaller cross-sectional studies of populations with other ethnicities. Observational studies on alcohol consumption are susceptible to confounding and reverse causation. By design, all study participants were young and relatively healthy, which minimizes influences of reverse causality. The associations were also essentially unaltered when excluding non-drinkers; the results are thus unlikely to be influenced by those who may have stopped drinking for health reasons. All results were similar when adjusting for adiposity, smoking and physical activity, suggesting limited confounding by these risk factors clustering with alcohol intake. The lack of association with leptin, and the distinct metabolic association pattern from that caused by elevated BMI, make it implausible that the metabolic perturbations would be mediated via effects of alcohol on adiposity. However, dietary composition may potentially confound the results.

The consistency of the cross-sectional and longitudinal association patterns helps exclude influence of unmeasured confounders that are fixed individual characteristics; however, we acknowledge that the longitudinal associations remain susceptible to other types of confounding. Nevertheless, missingness and inaccurate reporting of alcohol intake may still bias the reported point estimates, and likely underestimate the magnitude of the metabolic associations. The majority of study participants consumed alcohol only in low or moderate amounts, which prevents inferences about the metabolic associations with heavy alcohol consumption. Metabolomics of interventional studies could clarify whether the diverse metabolic changes arise due to short-term effects of alcohol intake or chronic exposure, for instance mediated via impaired liver function. Further studies may also characterize the metabolic effects of binge drinking, specific beverage types and whether the circulating markers of alcohol consumption could benefit identification of individuals at risk for alcoholic liver disease.

In conclusion, metabolic profiling of three large population-based cohorts identified novel metabolic markers for dose-dependent alcohol intake. The detailed metabolic phenotyping further clarified the association shapes for numerous established biomarkers related to alcohol and cardiometabolic risk. The metabolic signature of alcohol consumption included molecular perturbations linked with both higher and lower cardiovascular risk. Many metabolic measures displayed an optimum level at modest alcohol intake. The striking match between the overall cross-sectional and longitudinal association patterns provides evidence in support of the metabolic changes arising, at least partly, due to alcohol consumption. Comprehensive metabolic profiling in these large cohorts thus elucidated the metabolic influences of alcohol consumption and clarified the double-edged relation between alcohol and cardiometabolic biomarkers.

**Supplementary Data**
Supplementary data are available at IJE online.

**Funding**
This study was supported by Strategic Research Funding from the University of Oulu, Sigrid Juselius Foundation, Academy of Finland (grant numbers 250422, 139635), Novo Nordisk Foundation, Paavo Nurmi Foundation, Yrjö Jahnsson Foundation, Emil Aaltonen Foundation, Finnish Diabetes Research Foundation, Finnish Foundation for Cardiovascular Research and UK Medical Research Council via the University of Bristol Integrative Epidemiology Unit (MC_UU_12013/1 and MC_UU_12013/5). The Cardiovascular Risk in Young Finns Study is supported by Academy of Finland (286284,

References


